Automating a Design Platform for Solubilized Formulations


Automating a Design Platform for Solubilized Formulations

Agere to Present at IQPC 7thAnnual "Improving Solubility" Conference

BEND, Ore.--(BUSINESS WIRE)-- Agere Pharmaceuticals, Inc., a leading oral bioavailability contract research and manufacturing organization (CRO/CMO), will present at IQPC's "7th Annual Improving Solubility" Conference in Philadelphia.

CONFERENCE: IQPC 7th Annual Improving Solubility Conference February 26-28, 2013 Philadelphia, PA

WHAT:Presentation: "Amorphous Solid Dispersions: Toward a Predictable Science"

  • A new approach to make formulation a rigorous, predictable science

  • A proposal for automation enabled by a physical chemistry foundation

  • Agere's progress to date toward the goal

WHO: Marshall Crew, President and CEO, Agere

For more information, or to set up a private meeting, please contact us at

About Agere

Agere is a leading CRO/CMO focused on improving the oral bioavailability of insoluble APIs. The company supports clients from formulation design and development through cGMP manufacturing for Phase I through Phase IIb clinical trials. Agere is expert in solid dispersion techniques including spray drying and hot melt extrusion (HME), and in a broad selection of solid dosage forms. All services are delivered on a fee-for-service basis, and every project the company undertakes is customized to serve each individual client's requirements. Agere is located in Bend, OR. For information:

Agere Pharmaceuticals, Inc.
Sheri' DuMond, Director of Business Development, 541-639-8397
Cell: 541-508-9285

KEYWORDS: United States North America Oregon


The article Automating a Design Platform for Solubilized Formulations originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.